<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">microbe</journal-id><journal-title-group><journal-title xml:lang="ru">Проблемы особо опасных инфекций</journal-title><trans-title-group xml:lang="en"><trans-title>Problems of Particularly Dangerous Infections</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0370-1069</issn><issn pub-type="epub">2658-719X</issn><publisher><publisher-name>Russian Research Anti-Plague Institute “Microbe”</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21055/0370-1069-2026-1-145-151</article-id><article-id custom-type="elpub" pub-id-type="custom">microbe-2294</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Оценка коллективного иммунитета к вирусу SARS-CoV-2 среди населения Кыргызской Республики в период пандемии COVID-19</article-title><trans-title-group xml:lang="en"><trans-title>Assessment of Herd Immunity to SARS-CoV-2 Virus among the Population of the Kyrgyz Republic during COVID-19 Pandemic</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нуридинова</surname><given-names>Ж. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Nuridinova</surname><given-names>Zh. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Нуридинова Жанылай Нуридиновна</p><p>720005, Бишкек, ул. Байтик Баатыра, 34; Чуйская область, Ысык-Атинский район, Кант, ул. Гагарина, 58</p></bio><bio xml:lang="en"><p>Zhanylai N. Nuridinova</p><p>34, Baytik Baatyr St., Bishkek, 720005; 58, Gagarina St., Kant, Isyk-Ata District, Chui Region</p></bio><email xlink:type="simple">janylay35@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нурматов</surname><given-names>З. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Nurmatov</surname><given-names>Z. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>720005, Бишкек, ул. Байтик Баатыра</p></bio><bio xml:lang="en"><p>34, Baytik Baatyr St., Bishkek, 720005</p></bio><email xlink:type="simple">nphi.mhkr@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кучук</surname><given-names>Т. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuchuk</surname><given-names>T. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>720005, Бишкек, ул. Байтик Баатыра, 34</p></bio><bio xml:lang="en"><p>34, Baytik Baatyr St., Bishkek, 720005</p></bio><email xlink:type="simple">nphi.mhkr@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Касымбекова</surname><given-names>К. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Kasymbekova</surname><given-names>K. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>720040, Бишкек, ул. Орозбекова, 52/54</p></bio><bio xml:lang="en"><p>52/54, Orozbekov St., Bishkek, 720040</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Касымбеков</surname><given-names>Ж. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Kasymbekov</surname><given-names>Zh. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>720005, Бишкек, ул. Байтик Баатыра, 34</p></bio><bio xml:lang="en"><p>34, Baytik Baatyr St., Bishkek, 720005</p></bio><email xlink:type="simple">nphi.mhkr@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Национальный институт общественного здоровья Министерства здравоохранения Кыргызской Республики; Азиатский медицинский институт имени Саткынбая Тентишева<country>Кыргызстан</country></aff><aff xml:lang="en">National Institute of Public Health, Ministry of Health of the Kyrgyz Republic; Asian Medical Institute named after Satkynbay Tentishev<country>Kyrgyzstan</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Национальный институт общественного здоровья Министерства здравоохранения Кыргызской Республики<country>Кыргызстан</country></aff><aff xml:lang="en">National Institute of Public Health, Ministry of Health of the Kyrgyz Republic<country>Kyrgyzstan</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">Страновой офис ВОЗ в Кыргызстане<country>Кыргызстан</country></aff><aff xml:lang="en">WHO Country Office in Kyrgyzstan<country>Kyrgyzstan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>30</day><month>03</month><year>2026</year></pub-date><volume>0</volume><issue>1</issue><fpage>145</fpage><lpage>151</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Нуридинова Ж.Н., Нурматов З.Ш., Кучук Т.Э., Касымбекова К.Т., Касымбеков Ж.О., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Нуридинова Ж.Н., Нурматов З.Ш., Кучук Т.Э., Касымбекова К.Т., Касымбеков Ж.О.</copyright-holder><copyright-holder xml:lang="en">Nuridinova Z.N., Nurmatov Z.S., Kuchuk T.E., Kasymbekova K.T., Kasymbekov Z.O.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.microbe.ru/jour/article/view/2294">https://journal.microbe.ru/jour/article/view/2294</self-uri><abstract><p>В статье представлены результаты трех этапов сероэпидемиологического исследования населения на наличие антител к вирусу SARS-CoV-2.</p><p>Целью исследования была оценка коллективного иммунитета у населения Кыргызской Республики, стратифицированного по возрасту, полу и региону.</p><sec><title>Материалы и методы</title><p>Материалы и методы. Материалом для исследования послужили образцы крови и персональные данные (анкеты) лиц, давших согласие на участие в исследовании.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Результаты трех раундов исследования показали, что доля серопревалентных лиц на 1-м этапе составила 30,8 % (95 % ДИ 29,5–32,1), на 2-м этапе – 71,2 % (95 % ДИ 69,9– 72,5), на 3-м – 92,3 % (95 % ДИ 91,5–93,1). Высокий уровень коллективного иммунитета в популяции определялся коротким периодом и низким уровнем заболеваемости в четвертую волну пандемии по сравнению с мировыми показателями четвертой волны COVID-19. Неравномерное территориальное распределение серопревалентности наблюдалось на протяжении всех раундов исследования. Для всех трех фаз исследования характерно отсутствие симптомов коронавирусной инфекции у части серопозитивных лиц. Показатели наличия симптомов у серопозитивных лиц на втором и третьем этапах имели тенденцию к снижению. Процент серопозитивных к вирусу SARS-CoV-2 лиц среди детей был ниже, чем среди взрослого населения. Доля серопозитивных лиц ниже у мужчин по сравнению с женщинами. Анализ результатов сравнения парных сывороток, собранных через 8–20 месяцев, показал снижение уровня антител на 64,6 % по сравнению с результатом первой пробы, полученной через 1–2 месяца после болезни, в то же время повышенный уровень антител наблюдался у 35,4 % лиц.</p></sec></abstract><trans-abstract xml:lang="en"><p>This paper presents the results of a three round seroepidemiological study of the population for SARS-CoV-2 virus antibodies presence.</p><p>The aim of the study was to assess herd immunity in the population of the Kyrgyz Republic stratified by age, gender and region.</p><sec><title>Materials and methods</title><p>Materials and methods. The material for the study was blood samples and personal data (questionnaire) of individuals, who agreed to participate in the study.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. The results of the three rounds study indicated that the proportion of seroprevalent persons at the 1st round was 30.8% (95% CI 29.5-32.1), at the 2nd round 71.2% (95% CI 69.9-72.5), at the 3rd round 92.3% (95% CI 91.5-93.1). High herd immunity in the population was defined by short-term and low incidence in the fourth wave of the pandemic compared to the global indicators of the COVID-19 fourth wave. Uneven territorial distribution of seroprevalence was observed through all rounds of the study. All three rounds of the study were characterized by the lack of coronavirus infection symptoms in some of the seropositive individuals. Symptoms presence in seropositive individuals in the second and third rounds tended to decrease compared to the 1st round results in general. The percentage of SARS-CoV-2 virus seropositive individuals among children was lower versus the adult population. The share of seropositive samples was less for men compared to women. Paired sera examination, collected after 8-20 months, showed the decreased level of antibodies by 64.6% compared to those collected 1-2 months after the disease. At the same time, an increased level of antibodies was observed in 35.4% of individuals.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>популяционный иммунитет</kwd><kwd>пандемия</kwd><kwd>серопревалентность</kwd><kwd>коронавирус</kwd><kwd>сероэпидемиологическое исследование</kwd><kwd>заболеваемость</kwd></kwd-group><kwd-group xml:lang="en"><kwd>population immunity</kwd><kwd>pandemic</kwd><kwd>seroprevalence</kwd><kwd>coronavirus</kwd><kwd>seroepidemiological study</kwd><kwd>incidence</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Авторы заявляют об отсутствии дополнительного финансирования при проведении данного исследования. Мы выражаем глубокую благодарность страновому офису ВОЗ в Кыргызстане и ЕВРО ВОЗ за техническую помощь в проведении сероэпидемиологического исследования на наличие антител к SARS-CoV-2 в Кыргызской Республике. Также мы хотели бы поблагодарить сотрудников медицинских организаций Кыргызской Республики за их участие и поддержку, оказанную в ходе этого исследовани</funding-statement></funding-group><funding-group xml:lang="en"><funding-statement>The authors declare no additional financial support for this study. We express our deep gratitude to the WHO Country Office in Kyrgyzstan and WHO EURO for technical assistance in conducting the seroepidemiological study for the presence of SARS-CoV-2 antibodies in the Kyrgyz Republic. Also, we would like to thank employees of health care organizations of the Kyrgyz Republic for their participation and support provided during this study</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Islam A., Ahmed A., Naqvi I.H., Parveen S. Emergence of deadly severe acute respiratory syndrome coronavirus-2 during 20192020. VirusDisease. 2020; 31(2):128-36. DOI: 10.1007/s13337-020-00575-1.</mixed-citation><mixed-citation xml:lang="en">Islam A., Ahmed A., Naqvi I.H., Parveen S. Emergence of deadly severe acute respiratory syndrome coronavirus-2 during 20192020. VirusDisease. 2020; 31(2):128-36. DOI: 10.1007/s13337-020-00575-1.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. (Cited 10 Jan 2024). [Internet]. Available from: https://www.who.int/news-room/speeches/item/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020?ysclid=mlhnsug1kl945392527.</mixed-citation><mixed-citation xml:lang="en">WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. (Cited 10 Jan 2024). [Internet]. Available from: https://www.who.int/news-room/speeches/item/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020?ysclid=mlhnsug1kl945392527.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Operational Summary, Ministry of Health of the Kyrgyz Republic. Available from: https://med.kg/.</mixed-citation><mixed-citation xml:lang="en">Operational Summary, Ministry of Health of the Kyrgyz Republic. Available from: https://med.kg/.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Wolff F., Dahma H., Duterme C., Van den Wijngaert S., Vandenberg O., Cotton F., Montesinos I. Monitoring antibody response following SARS-CoV-2 infection: diagnostic efficiency of 4 automated immunoassays. Diagn. Microbiol. Infect. Dis. 2020; 98(3):115140. DOI: 10.1016/j.diagmicrobio.2020.115140.</mixed-citation><mixed-citation xml:lang="en">Wolff F., Dahma H., Duterme C., Van den Wijngaert S., Vandenberg O., Cotton F., Montesinos I. Monitoring antibody response following SARS-CoV-2 infection: diagnostic efficiency of 4 automated immunoassays. Diagn. Microbiol. Infect. Dis. 2020; 98(3):115140. DOI: 10.1016/j.diagmicrobio.2020.115140.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Rostami A., Sepidarkish M., Leeflang M.M.G., Riahi S.M., Nourollahpour Shiadeh M., Esfandyari S., Mokdad A.H., Hotez P.J., Gasser R.B. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin. Microbiol. Infect. 2021; 27(3):331-40. DOI: 10.1016/j.cmi.2020.10.020.</mixed-citation><mixed-citation xml:lang="en">Rostami A., Sepidarkish M., Leeflang M.M.G., Riahi S.M., Nourollahpour Shiadeh M., Esfandyari S., Mokdad A.H., Hotez P.J., Gasser R.B. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin. Microbiol. Infect. 2021; 27(3):331-40. DOI: 10.1016/j.cmi.2020.10.020.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Nikitin A.Ya., Chesnokova M.V., Balakhonov S.V. [Algorithm and results of a short-term forecast of changes in the COVID-19 spread coefficient in the constituent entities of the Russian Federation]. Problemy Osobo Opasnykh Infektsii [Problems of Particularly Dangerous Infections]. 2021; (3):98-105. (In Russian). DOI: 10.21055/0370-1069-2021-3-98-105.</mixed-citation><mixed-citation xml:lang="en">Nikitin A.Ya., Chesnokova M.V., Balakhonov S.V. [Algorithm and results of a short-term forecast of changes in the COVID-19 spread coefficient in the constituent entities of the Russian Federation]. Problemy Osobo Opasnykh Infektsii [Problems of Particularly Dangerous Infections]. 2021; (3):98-105. (In Russian). DOI: 10.21055/0370-1069-2021-3-98-105.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Open Source Epidemiological Statistics for Public Health. (Cited 15 Jan 2024). [Internet]. Available from: http://www.openepi.com/Menu/OE_Menu.htm.</mixed-citation><mixed-citation xml:lang="en">Open Source Epidemiological Statistics for Public Health. (Cited 15 Jan 2024). [Internet]. Available from: http://www.openepi.com/Menu/OE_Menu.htm.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Nuridinova Zh.N., Nurmatov Z.Sh., Kuchuk T.E., Kasymbekova K.K. Dynamics of the development of the epidemic of coronavirus infection and assessment of population immunity to SARS-COV-2 in the territory of the Kyrgyz Republic. Heart Vessels Transplant. 2024; 8. DOI: 10.24969/hvt.2023.455.</mixed-citation><mixed-citation xml:lang="en">Nuridinova Zh.N., Nurmatov Z.Sh., Kuchuk T.E., Kasymbekova K.K. Dynamics of the development of the epidemic of coronavirus infection and assessment of population immunity to SARS-COV-2 in the territory of the Kyrgyz Republic. Heart Vessels Transplant. 2024; 8. DOI: 10.24969/hvt.2023.455.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ludvigson J.F. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Pediatr. 2020; 109(6):1088-95. DOI: 10.1111/apa.15270.</mixed-citation><mixed-citation xml:lang="en">Ludvigson J.F. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Pediatr. 2020; 109(6):1088-95. DOI: 10.1111/apa.15270.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Xia J., Yu T., Zhang X., Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507-13. DOI: 10.1016/S0140-6736(20)30211-7.</mixed-citation><mixed-citation xml:lang="en">Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Xia J., Yu T., Zhang X., Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507-13. DOI: 10.1016/S0140-6736(20)30211-7.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wang W., Tang J., Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J. Med. Virol. 2020; 92(4):441-7. DOI: 10.1002/jmv.25689.</mixed-citation><mixed-citation xml:lang="en">Wang W., Tang J., Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J. Med. Virol. 2020; 92(4):441-7. DOI: 10.1002/jmv.25689.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
